因果机器学习技术开发商PhaseV获得5000万美元A轮融资，加速临床开发中的人工智能应用，受到顶级风险投资公司支持，并赢得领先制药客户的信赖-动脉网

PhaseV Lands $50M Series A to Supercharge AI for Clinical Development, Backed by Top VCs and Trusted by Leading Pharma Clients

CISION 等信源发布 2025-05-13 21:00



可切换为仅中文







With a Growing List of 30+ Global Customers, Including Top Pharma, PhaseV is Poised to Transform Clinical Development at Scale with its Vertical AI Platform

随着全球客户名单不断增长，现已超过30家，其中包括顶级制药公司，PhaseV凭借其垂直人工智能平台，准备大规模变革临床开发。

BOSTON

波士顿

，

May 13, 2025

2025年5月13日

/PRNewswire/ --

PhaseV

第五阶段

, a leader in AI/ML-driven clinical development, today announced the completion of a

，一家在人工智能/机器学习驱动的临床开发领域的领导者，今天宣布完成了

$50 million

5000万美元

Series A funding round. Co-led by

A轮融资。由以下公司共同领投

Accel

加速器

and

和

Insight Partners

洞察合作伙伴

and with participation of existing investors Viola Ventures, EXOR and LionBird, the round brings the company's total funding to date to

现有投资者 Viola Ventures、EXOR 和 LionBird 也参与其中，此轮融资使该公司迄今为止的总融资额达到

$65 million

6500万美元

。

继续阅读

PhaseV Co-founders Raviv Pryluk and Elad Berkman. Image credit: Eyal Toueg and TheMarker

PhaseV 联合创始人拉维夫·普里卢克和埃拉德·伯克曼。图片来源：艾亚尔·图埃格和 TheMarker

'The pharma industry is at a critical crossroads, as traditional approaches to designing and executing clinical trials struggle to meet growing demands for speed, cost-efficiency, and higher success rates,' said Raviv Pryluk, PhD, CEO and Co-Founder of PhaseV. 'This funding fuels our mission to support more pharma, biotech, and CROs in embracing AI and machine learning to unlock the next era of clinical development.

“制药行业正处于一个关键的十字路口，传统的方法在设计和执行临床试验时难以满足对速度、成本效益和更高成功率日益增长的需求，”PhaseV首席执行官兼联合创始人拉维夫·普里卢克博士说道。“这笔资金将推动我们的使命，支持更多制药公司、生物技术公司和合同研究组织（CRO）采用人工智能和机器学习，开启临床开发的新时代。”

Our solutions deliver clear ROI by increasing trial success rates, reducing costs, and accelerating time to market.'.

我们的解决方案通过提高试验成功率、降低成本并加快上市时间，带来了明确的投资回报率。

The funding will allow PhaseV to grow its vertical AI platform to provide holistic solutions for clinical development. It follows the rapid market adoption of PhaseV's AI/ML-based platform by over 30 global pharma companies for clinical development. The platform is currently used across more than 20 therapeutic areas, including neurology, oncology, GI disorders, immunology, metabolic diseases, rare diseases, and others..

这笔资金将使PhaseV能够扩展其垂直人工智能平台，为临床开发提供整体解决方案。此前，PhaseV基于人工智能/机器学习的平台已被超过30家全球制药公司迅速采用，用于临床开发。该平台目前已应用于超过20个治疗领域，包括神经学、肿瘤学、胃肠疾病、免疫学、代谢疾病、罕见病等。

Augmented by a robust data lake that integrates high quality patient-level data, clinical trial results, real-world evidence, and peer-reviewed insights, PhaseV's platform has demonstrated a reduction in trial costs by 50%, a decrease in enrollment size and trial duration by 40%, and a more than 30% increase in the likelihood of trial success.

通过一个强大的数据湖的增强，该数据湖整合了高质量的患者层面数据、临床试验结果、真实世界证据和经过同行评审的见解，PhaseV 的平台已经展示了将试验成本减少 50%、入组规模和试验时长减少 40%，以及试验成功可能性提高 30% 以上的成果。

In one recent example, PhaseV helped a leading global pharma company to shorten time-to-market by 15 months..

在最近的一个例子中，PhaseV帮助了一家全球领先的制药公司将其产品上市时间缩短了15个月。

'PhaseV is one of the most exciting companies on the rise and, with this financial backing, is positioned to lead the revolution of AI in clinical development,' said

“PhaseV 是一家非常令人兴奋的新兴公司，有了这笔资金支持，它将引领人工智能在临床开发领域的革命。”

Matt Robinson

马特·罗宾逊

, Partner at Accel. 'We have been impressed with PhaseV's ability to partner with the world's largest pharma companies, which illustrates how hungry the market is for the company's technology. We're thrilled to back PhaseV and excited to see their continued growth and impact on the future of clinical development.'.

，Accel的合伙人。“PhaseV与全球最大的制药公司合作的能力给我们留下了深刻印象，这表明市场对该公司技术的需求非常迫切。我们很高兴支持PhaseV，并期待看到他们在临床开发未来中的持续成长和影响。”

PhaseV's vertical AI platform supports end-to-end clinical development from design through execution. It currently comprises four core applications:

PhaseV的垂直人工智能平台支持从设计到执行的端到端临床开发。它目前包括四个核心应用：

Trial Optimizer

试验优化器

for optimizing and implementing Bayesian, adaptive, and fixed trials;

用于优化和实施贝叶斯、自适应和固定试验；

Causal ML

因果机器学习

for heterogeneous treatment effect estimation to uncover hidden signals in clinical data and identify subpopulations and endpoints with the highest potential for success;

用于异质性治疗效果估计，以揭示临床数据中的隐藏信号，并确定成功潜力最大的亚群和终点；

Causal Disease Modeling

因果疾病建模

to inform new R&D and life cycle management; and

告知新的研发和生命周期管理；以及

Clinical Operations

临床操作

for Causal ML-driven site selection, site performance analytics, real-time trial progress monitoring, and integration of virtual control arms.

用于因果机器学习驱动的站点选择、站点绩效分析、实时试验进度监控以及虚拟对照组的整合。

'We worked with PhaseV on one of our recent trials to identify clinically meaningful subgroups using Causal ML. Their expertise helped us identify a promising subpopulation that otherwise would not have been detected. They collaborated with our internal teams to ensure the findings drove real value for our development plan,״ said .

“我们与PhaseV合作进行了最近的一项试验，利用因果机器学习来识别具有临床意义的亚组。他们的专业知识帮助我们发现了一个有前景的亚群，否则可能无法被检测到。他们与我们的内部团队协作，确保研究结果为我们的开发计划带来了真正的价值。”

Stu Bailey

斯图·贝利

, D.Phil., SVP Head of Clinical Measurement Sciences at EMD Serono. 'We see opportunity to continue this collaboration with PhaseV as we seek to increase probability of success and drive efficiencies across our clinical portfolio.'

，哲学博士，EMD Serono临床测量科学高级副总裁。 “随着我们寻求增加成功的可能性并提高整个临床组合的效率，我们看到与PhaseV继续合作的机会。”

'As clinical trials rapidly evolve, accuracy remains critical for biotech companies. PhaseV enables this precision, paving the way for a new era of clinical development,' said

“随着临床试验的迅速发展，精确性对生物技术公司仍然至关重要。PhaseV实现了这种精确性，为临床开发的新时代铺平了道路，”

Dylan Morris

迪伦·莫里斯

, Managing Director at Insight Partners. 'They are already delivering promising results, proving the power of their AI-driven approach. This funding demonstrates our confidence in PhaseV's potential to reshape trial design, accelerate the drug development process and bring new therapies to market faster.

，Insight Partners董事总经理。“他们已经取得了可喜的成果，证明了其人工智能驱动方法的强大。这笔资金表明了我们对PhaseV重塑试验设计、加速药物开发进程并更快地将新疗法推向市场的潜力充满信心。

PhaseV has ambitious plans to add more capabilities and it's an exciting time to join them on the journey to change the world for the better.'.

PhaseV 有着增加更多能力的宏伟计划，现在加入他们、踏上让世界变得更美好的旅程，正是一个激动人心的时刻。

About PhaseV

关于PhaseV

PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive, Bayesian and fixed clinical trials, analyze data to uncover heterogeneous treatment effects, stratify patients, and inform future R&D and portfolio decisions.

PhaseV 正在开发先进的 AI/ML 解决方案，以优化临床开发。生物制药公司和合同研究组织 (CRO) 正利用 PhaseV 的平台快速设计和执行适应性、贝叶斯和固定临床试验，分析数据以揭示异质性治疗效果，对患者进行分层，并为未来的研发和产品组合决策提供信息。

PhaseV's platform has reduced trial costs by 50%, decreased enrollment size and trial duration by 40%, and increased the probability of trial success by over 30%. To date, the company has delivered results for more than 30 leading pharma/biotech sponsors and CROs spanning multiple therapeutic areas, including neurology, oncology, immunology, GI, rare diseases, and others..

PhaseV的平台将试验成本降低了50%，试验规模和持续时间减少了40%，并将试验成功的概率提高了30%以上。迄今为止，该公司已经为30多家领先的制药/生物技术赞助商和CRO提供了成果，涵盖多个治疗领域，包括神经病学、肿瘤学、免疫学、胃肠病学、罕见病等。

Learn more at

了解更多请访问

www.PhaseVTrials.com

and follow us on

并关注我们

领英

。

Media Contact:

媒体联系人：

Ellie Hanson

艾莉·汉森